@article {117, title = {Inhibition of MDR1 in mammary cell carcinoma reverses Multidrug Resistance by SOCS1}, journal = {Pharmacognosy Journal}, volume = {8}, year = {2016}, month = {09/2015}, pages = {103-112}, type = {Original Article}, chapter = {103}, abstract = {

Introduction: Suppressors of cytokine signalling (SOCS1), a newly indentified antiapoptotic molecule is a downstream effector of the receptor tyrosine kinase-Ras signalling pathway. Current study has uncovered that SOCS1 may have wide and imperative capacities, particularly because of its close correlation with malignant tumors. Methods: To investigate the impact of SOCS1 on MDR, we analyzed the expression of P-gp and SOCS1 by immunohistochemistry and found there was positive correlation between them. At that point we effectively interfered with RNA translation by the contamination of siRNA of SOCS1 into MCF7/ ADM breast cancer cell lines through a lentivirus, and the expression of the target gene was significantly inhibited. Results: After RNAi the drug resistance was reduced altogether and the expression of MDR1 mRNA and P-gp in MCF7/ADM cell lines demonstrated a significant decrease. Likewise the expression of P53 protein increased in a statistically significant manner (p\≤0.01) after RNAi exposure. Moreover, flow cytometry analysis uncovers that cell cycle and anti-apoptotic enhancing capacity of cells changed after RNAi treatment. Conclusion: These outcomes proposed SOCS1 may take part in breast cancer MDR by managing MDR1 and P53 expression, changing cell cycle and enhancing the anti-apoptotic ability of cells.

}, keywords = {Breast cancer, MDR1gene, Multidrug resistance, RNA interference., SOCS1 gene}, doi = {10.5530/pj.2016.2.2}, author = {Debasish Pradhan and Gitanjali Tripathy and Rakesh Kumar Pradhan and Shaktiprasad Pradhan and Soumyashree Rupambika Moharana} }